So far, two pharmaceutical industry companies have disclosed their performance reports for the first half of 2024, namely Temple of Heaven Biology and Walter Dyne.According to the express, both companies have achieved positive performance growth.

Among them, according to the performance express released by Temple of Heaven Biology on the evening of July 12, the company achieved a net profit of 726 million yuan in the first half of 2024, an increase of 28.12% year-on-year.Regarding the growth of performance in the first half of 2024, Temple of Heaven Biology said that it was mainly due to factors such as product prices and cost control, which led to an increase in sales revenue and an increase in profit margins.

It is understood that Tiantan Biological is mainly engaged in the research and development, production and sales of blood products. It currently has 15 varieties of blood products. The two main products are human albumin and intravenous human immunoglobulin (also known as “Jingpeng”).In 2023, the revenue of these two products will be 2.247 billion yuan and 2.319 billion yuan, respectively, accounting for 43.38% and 44.77% of the total revenue of Temple of Heaven Biology.

As a domestic blood products company, Temple of Heaven Biology has been benchmarking international blood products companies, paying close attention to industry trends, and ensuring the continuous improvement of the layout of R&D pipelines.The advanced design of the R&D system and the relatively perfect layout of the R&D pipeline have made Tiantan Biological the only company in the domestic blood products industry that has obtained the listing license of recombinant human coagulation factor products.